Dianthus Therapeutics, Inc. /DE/ financial data

Symbol
DNTH on Nasdaq
Industry
Pharmaceutical Preparations
Location
7 Times Square, 43 Rd Floor, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
Magenta Therapeutics, Inc. (to 9/8/2023)
Latest financial report
10-K - Q4 2024 - Mar 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.47K % +52.5%
Debt-to-equity 4.11 % -72.1%
Return On Equity -23.9 % +67.7%
Return On Assets -23 % +29.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.1M shares +9.47%
Common Stock, Shares, Outstanding 31.1M shares +110%
Entity Public Float 651M USD +1928%
Common Stock, Value, Issued 31K USD +107%
Weighted Average Number of Shares Outstanding, Basic 33.3M shares +546%
Weighted Average Number of Shares Outstanding, Diluted 33.3M shares +546%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 924K USD -21.2%
Research and Development Expense 83.1M USD +153%
General and Administrative Expense 25M USD +37.6%
Operating Income (Loss) -102M USD -111%
Nonoperating Income (Expense) 16.9M USD +266%
Net Income (Loss) Attributable to Parent -85M USD -95.1%
Earnings Per Share, Basic -2.55 USD/shares +69.8%
Earnings Per Share, Diluted -2.55 USD/shares +69.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22.8M USD -82.8%
Cash, Cash Equivalents, and Short-term Investments 21.9M USD -83.3%
Accounts Receivable, after Allowance for Credit Loss, Current 807K USD +174%
Other Assets, Current 355K USD
Assets, Current 281M USD +58.3%
Property, Plant and Equipment, Net 194K USD +4.87%
Operating Lease, Right-of-Use Asset 1.55M USD +153%
Assets 374M USD +108%
Accounts Payable, Current 4.58M USD +75.4%
Employee-related Liabilities, Current 5.15M USD -3.86%
Accrued Liabilities, Current 13.1M USD +101%
Liabilities, Current 18.5M USD +91.6%
Operating Lease, Liability, Noncurrent 1.17M USD +597%
Liabilities 21.5M USD +104%
Accumulated Other Comprehensive Income (Loss), Net of Tax 106K USD +126%
Retained Earnings (Accumulated Deficit) -174M USD -95%
Stockholders' Equity Attributable to Parent 352M USD +109%
Liabilities and Equity 374M USD +108%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.9M USD -45.3%
Net Cash Provided by (Used in) Financing Activities 218M USD
Net Cash Provided by (Used in) Investing Activities -5.51M USD -130%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 31.1M shares +110%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 197M USD +2416%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 23M USD -82.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 182M USD +47.1%
Deferred Tax Assets, Gross 182M USD +33%
Operating Lease, Liability 1.49M USD +155%
Depreciation 96K USD +43.3%
Payments to Acquire Property, Plant, and Equipment 245K USD +807%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -84.9M USD -95.9%
Lessee, Operating Lease, Liability, to be Paid 1.92M USD +201%
Property, Plant and Equipment, Gross 387K USD +37.2%
Operating Lease, Liability, Current 320K USD -23.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 268K USD +20.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 322K USD -22.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure -18.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 431K USD +698%
Lessee, Operating Lease, Liability, to be Paid, Year Three 314K USD
Deferred Tax Assets, Operating Loss Carryforwards 110M USD +49%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 318K USD
Operating Lease, Payments 19.8M USD -100%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 421K USD -17.6%
Deferred Tax Assets, Net of Valuation Allowance 227K USD -98.3%
Share-based Payment Arrangement, Expense 12.9M USD +345%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%